Sigyn Therapeutics, Inc.
SIGY
$4.10
-$0.0099-0.24%
| Weiss Ratings | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Rating | ||||
| Reward Index | Very Weak | |||
| Risk Index | Very Weak | |||
| Risk Grade | E+ | |||
| Reward Grade | E | |||
| Rating Factors | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Dividend Index | -- | |||
| Growth Index | Weak | |||
| Efficiency Index | Very Weak | |||
| Solvency Index | Very Weak | |||
| Total Return Index | Very Weak | |||
| Volatility Index | Weak | |||
| Beta / Standard Deviation | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Beta | -0.03 | |||
| Price History | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 7-Day Total Return | -0.24% | |||
| 30-Day Total Return | 28.13% | |||
| 60-Day Total Return | -24.07% | |||
| 90-Day Total Return | -14.58% | |||
| Year to Date Total Return | 30.16% | |||
| 1-Year Total Return | -18.00% | |||
| 2-Year Total Return | -34.29% | |||
| 3-Year Total Return | -77.72% | |||
| 5-Year Total Return | -- | |||
| 52-Week High % Change | -35.33% | |||
| 52-Week Low % Change | 30.16% | |||
| Price | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| 52-Week High Price | $6.34 | |||
| 52-Week Low Price | $3.15 | |||
| 52-Week Low Price (Date) | Dec 17, 2024 | |||
| 52-Week High Price (Date) | Apr 26, 2024 | |||
| Valuation | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Market Cap | 6.58M | |||
| Enterprise Value | 8.39M | |||
| Price/Earnings (TTM) | -- | |||
| Earnings Per Share (TTM) | -3.23 | |||
| Earnings Per Share Growth | -14.93% | |||
| Price/Earnings To Growth | -- | |||
| Price/Sales (TTM) | -- | |||
| Price/Book (Q) | -1.48 | |||
| Enterprise Value/Revenue (TTM) | -- | |||
| Price | $4.10 | |||
| Enterprise Value/EBITDA (TTM) | -3.05 | |||
| Enterprise Value/EBIT | -3.04 | |||
| Market Cap Category | Nano Cap | |||
| Dividends and Shares | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Shares Outstanding | 1.27M | |||
| Dividend Yield | -- | |||
| Div. Per Share (Most Recent) | -- | |||
| Dividend Per Share (TTM) | -- | |||
| Payout Ratio (TTM) | -- | |||
| Dividend Per Share (Most Recent) | -- | |||
| Company Info | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Phone Number | 619 353 0800 | |||
| Address | 2468 Historic Decatur Road San Diego, CA 92106 | |||
| Website | www.sigyntherapeutics.com | |||
| Country | United States | |||
| Year Founded | 2019 | |||
| Profitability | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Operating Margin (TTM) | -- | |||
| Profit Margin | -- | |||
| Management Effectiveness | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Return on Assets | -423.29% | |||
| Return on Equity | -- | |||
| Income Statement | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Revenue (TTM) | -- | |||
| Total Revenue (TTM) | -- | |||
| Revenue Per Share | -- | |||
| Gross Profit (TTM) | -- | |||
| EBITDA (TTM) | -2.75M | |||
| EBIT (TTM) | -2.76M | |||
| Net Income (TTM) | -3.99M | |||
| Net Income Avl. to Common (TTM) | -3.99M | |||
| Total Revenue Growth (Q YOY) | -- | |||
| Earnings Growth (Q YOY) | -32.15% | |||
| EPS Diluted (TTM) | -3.23 | |||
| EPS Diluted Growth (Q YOY) | -15.05% | |||
| Balance Sheet | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash and Short-Term Inv. (Q) | 164.80K | |||
| Cash Per Share (Q) | $0.13 | |||
| Total Current Assets (Q) | 269.10K | |||
| Total Preferred Equity (Q) | -- | |||
| Total Equity (Q) | -3.92M | |||
| Current Ratio (Q) | 0.063 | |||
| Book Value Per Share (Q) | -$2.76 | |||
| Total Assets (Q) | 427.40K | |||
| Total Current Liabilities (Q) | 4.28M | |||
| Total Debt (Q) | 1.98M | |||
| Total Liabilities (Q) | 4.35M | |||
| Total Common Equity (Q) | -3.92M | |||
| Cash Flow | SIGY - OTC PK | Click to Compare |
Click to Compare |
Click to Compare |
| Cash from Investing (TTM) | -- | |||
| Cash from Financing (TTM) | 810.40K | |||
| Net Change in Cash (TTM) | 100.10K | |||
| Levered Free Cash Flow (TTM) | 600.00K | |||
| Cash from Operations (TTM) | -710.10K | |||
